Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(ε-caprolactone) micelles

Journal of Controlled Release

Volumn 116, Issue 2 SPEC. ISS., 2006, Pages 139-149

  Forrest, M Laird ^a   Zhao, Anni ^a   Won, Chee Youb ^b   Malick, A Waseem ^b   Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Geldanamycin; Hsp90; Nanocarrier; Poly(ethylene glycol) b poly( caprolactone); Polymer micelle

Indexed keywords

BLOCK COPOLYMERS; ENCAPSULATION; ENZYME INHIBITION; FATTY ACIDS; MICELLES; NANOSTRUCTURED MATERIALS; POLYETHYLENE GLYCOLS;

GELDANAMYCIN; LIPOPHILIC PRODRUGS; NANOCARRIER; POLYMER MICELLE;

ANTIBIOTICS;

17 (ETHYLAMINO 2 BROMODODECONATE) 17 DEMETHOXYGELDANAMYCIN; 17 (ETHYLAMINO 2 BROMOHEXANATE) 17 DEMETHOXYGELDANAMYCIN; 17 (ETHYLAMINO 2 BROMOPALMITATE) 17 DEMETHOXYGELDANAMYCIN; 17 (ETHYLAMINO 2 DODECONATE) 17 DEMETHOXYGELDANAMYCIN; 17 (ETHYLAMINO 2 HEXANATE) 17 DEMETHOXYGELDANAMYCIN; 17 (ETHYLAMINO 2 PALMITATE) 17 DEMETHOXYGELDANAMYCIN; 17 AMINOHEXADECANE 17 DEMETHOXYGELDANAMYCIN; 17BETA HYDROXYETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; COPOLYMER; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; POLY(ETHYLENE GLYCOL) B POLY(SIGMA CAPROLACTONE); PRODRUG;

ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; HUMAN CELL; LIPOPHILICITY; MICELLE; PRIORITY JOURNAL; SOLVENT EXTRACTION;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; ETHYLENE GLYCOLS; HALF-LIFE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; KINETICS; LACTAMS, MACROCYCLIC; MICELLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYESTERS; PRODRUGS; SOLUBILITY;

EID: 33845214383     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.07.003     Document Type: Article

References (51)

1. Goetz M.P., Toft D.O., Ames M.M., and Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. 14 (2003) 1169-1176
2. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 (1999) 260-266
3. Citri A., Kochupurakkal B.S., and Yarden Y. The Achilles' heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3 (2004) 51-60
4. Yu D., Liu B., Jing T., Sun D., Price J.E., Singletary S.E., Ibrahim N., Hortobagyi G.N., and Hung M.C. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16 (1998) 2087-2094
5. Supko J.G., Hickman R.L., Grever M.R., and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36 (1995) 305-315
6. Sausville E.A., Tomaszewski J.E., and Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 3 (2003) 377-383
7. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., Muzzi M.L., DiOrio C.I., Barbacci E.G., Miller P.E., et al. ErbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem. 38 (1995) 3813-3820
8. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., Simmons L., Maloney A., Raynaud F., Campbell M., Walton M., Lakhani S., Kaye S., Workman P., and Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 4152-4161
9. Mitsiades C.S., Mitsiades N., Rooney M., Hideshima T., Chauhan D., Munshi N.C., Johnson R., Hannah A., Richardson P.G., and Anderson K.C. Anti-tumor acitivity of KOS-953, a Cremophor-based formulation of the hsp90 inhibitor 17-AAG. Blood (ASH Annual Meeting Abstracts) vol. 104 (2004) Abstract 2404
10. Egorin M.J., Zuhowski E.G., Rosen D.M., Sentz D.L., Covey J.M., and Eiseman J.L. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol. 47 (2001) 291-302
11. Eiseman J.L., Lan J., Lagattuta T.F., Hamburger D.R., Joseph E., Covey J.M., and Egorin M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55 (2005) 21-32
12. Price J.T., Quinn J.M., Sims N.A., Vieusseux J., Waldeck K., Docherty S.E., Myers D., Nakamura A., Waltham M.C., Gillespie M.T., and Thompson E.W. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65 (2005) 4929-4938
13. Ibrahim N.O., Hahn T., Franke C., Stiehl D.P., Wirthner R., Wenger R.H., and Katschinski D.M. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res. 65 (2005) 11094-11100
14. Kurebayashi J., Otsuki T., Kurosumi M., Soga S., Akinaga S., and Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn. J. Cancer Res. 92 (2001) 1342-1351
15. Aliabadi H.M., Mahmud A., Sharifabadi A.D., and Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release 104 (2005) 301-311
16. Forrest M.L., Won C.Y., Malick A.W., and Kwon G.S. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. J. Control. Release 110 (2006) 370-377
17. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan Kim S., and Seo M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release 72 (2001) 191-202
18. Luo L., Tam J., Maysinger D., and Eisenberg A. Cellular internalization of poly(ethylene oxide)-b-poly(ε-caprolactone) diblock copolymer micelles. Bioconjug. Chem. 13 (2002) 1259-1265
19. DeBoer C., Meulman P.A., Wnuk R.J., and Peterson D.H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo) 23 (1970) 442-447
20. K, Sasaki., Y, Inoue., Geldanamycin derivatives and antitumor drug. US 4,261,989, April 14, 1981.
21. Soo P.L., Luo L., Maysinger D., and Eisenberg A. Incorporation and release of hydrophobic probes in biocompatible polycaprolactone-block-poly(ethylene oxide) micelles: implications for drug delivery. Langmuir 18 (2002) 9996-10004
22. Klotz W.L., Schure M.R., and Foley J.P. Determination of octanol-water partition coefficients of pesticides by microemulsion electrokinetic chromatography. J. Chromatogr., A 930 (2001) 145-154
23. Liu J., Xiao Y., and Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J. Pharm. Sci. 93 (2004) 132-143
24. Krevelen D.V. Cohesive properties and solubility. In: Krevelen D.V. (Ed). Properties of Polymers: Their Correlation with Chemical Structure (1990), Elsevier Scientific Pub. Co., New York 189-224
25. Vakil R., Kuldipkumar A., Andes D., Tan Y., and Kwon G.S. Polymeric micelles for the delivery of polyene antibiotics. In: Svenson S. (Ed). Polymeric Particulate Drug Carriers (2005), ACS Symposium Series, New York
26. Flory P.J. Thermodynamics of high polymer solutions. J. Chem. Phys. 9 (1941) 660
27. Hancock B.C., and Zografi G. The use of solution theories for predicting water vapor absorption by amorphous pharmaceutical solids: a test of the Flory-Huggins and Vrentas models. Pharm. Res. 10 (1993) 1262-1267
28. Nair R., Nyamweya N., Gonen S., Martinez-Miranda L.J., and Hoag S.W. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation. Int. J. Pharm. 225 (2001) 83-96
29. Lacoulonche F., Chauvet A., Masse J., Egea M.A., and Garcia M.L. An investigation of FB interactions with poly(ethylene glycol) 6000, poly(ethylene glycol) 4000, and poly-ε-caprolactone by thermoanalytical and spectroscopic methods and modeling. J. Pharm. Sci. 87 (1998) 543-551
30. Nagarajan R., Barry M., and Ruckenstein E. Unusual selectivity in solubilization by block copolymer micelles. Langmuir 2 (1986) 210-215
31. Shin I.G., Kim S.Y., Lee Y.M., Cho C.S., and Sung Y.K. Methoxy poly(ethylene glycol)/ε-caprolactone amphiphilic block copolymeric micelle containing indomethacin: I. Preparation and characterization. J. Control. Release 51 (1998) 1-11
32. Jette K.K., Law D., Schmitt E.A., and Kwon G.S. Preparation and drug loading of poly(ethylene glycol)-block-poly(ε-caprolactone) micelles through the evaporation of a cosolvent azeotrope. Pharm. Res. 21 (2004) 1184-1191
33. Ge H., Hu Y., Jiang X., Cheng D., Yuan Y., Bi H., and Yang C. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(ε-caprolactone)-poly(ethyleneoxide)-poly(ε-caprolactone) amphiphilic triblock copolymer micelles. J. Pharm. Sci. 91 (2002) 1463-1473
34. Allen C., Han J., Yu Y., Maysinger D., and Eisenberg A. Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J. Control. Release 63 (2000) 275-286
35. Cao Z., Harris N., Kozielski A., Vardeman D., Stehlin J.S., and Giovanella B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J. Med. Chem. 41 (1998) 31-37
36. Ali S., Ahmad I., Peters A., Masters G., Minchey S., Janoff A., and Mayhew E. Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities. Anticancer Drugs 12 (2001) 117-128
37. Rodrigues D.G., Maria D.A., Fernandes D.C., Valduga C.J., Couto R.D., Ibanez O.C., and Maranhao R.C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 55 (2005) 565-576
38. Barzilay E., Ben-Califa N., Supino-Rosin L., Kashman Y., Hirschberg K., Elazar Z., and Neumann D. Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity. J. Biol. Chem. 279 (2004) 6847-6852
39. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., Muzzi M.L., Moyer J.D., DiOrio C.I., Barbacci E.G., et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 38 (1995) 3806-3812
40. Cox B.G., and McTigue P.T. Kinetic medium effects: III. Solvent effects on A1 and A2 hydrolyses in water-dimethyl sulphoxide mixtures. Aust. J. Chem. 20 (1967) 1815-1822
41. National Cancer Institute Developmental Therapeutics Program Datawarehouse. http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp. Accessed March 13, 2006.
42. Li C., Yu D.F., Newman R.A., Cabral F., Stephens L.C., Hunter N., Milas L., and Wallace S. Complete regression of well-established tumors using novel water-soluble poly(l-glutamic acid)-paclitaxel conjugates. Cancer Res. 58 (1998) 2404-2409
43. Ulbrich K., Etrych T., Chytil P., Jelinkova M., and Øíhová B. HPMA copolymers with pH-controlled release of doxorubicin. In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 87 (2003) 33-47
44. Kasuya Y., Lu Z.R., Kopeckova P., Tabibi S.E., and Kopecek J. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm. Res. 19 (2002) 115-123
45. Poulin P., Schoenlein K., and Theil F.P. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. 90 (2001) 436-447
46. Lucangioli S.E., Kenndler E., Carlucci A., Tripodi V.P., Scioscia S.L., and Carducci C.N. Relation between retention factors of immunosuppressive drugs in microemulsion electrokinetic chromatography with biosurfactants and octanol-water partition coefficients. J. Pharm. Biomed. Anal. 33 (2003) 871-878
47. Marini A., Berbenni V., Bruni G., Cofrancesco P., Giordana F., and Villa M. Physico-chemical characterization of drugs and drug forms in the solid state. Curr. Med. Chem. Anti-Infect. Agents 2 (2003) 303-321
48. Johnson B.K., and Prud'homme R.K. Flash nanoprecipitation of organic actives and block copolymers using a confined impinging jets mixer. Aust. J. Chem. 56 (2003) 1021-1024
49. B.K. Johnson, R.K. Prud'homme, Mechanism for rapid self-assembly of block copolymer nanoparticles, Phys. Rev. Lett. 91 (2003) 118302.118301-118304.
50. Lee S.C., Change Y., Yoon J.-S., Kim C., Kwon I.C., Kim Y.-H., and Jeong S.Y. Synthesis and micellar characterization of amphiphilic diblock copolymers based on poly(2-ethyl-2-oxazoline) and aliphatic polyesters. Macromolecules 32 (1999) 1847-1852
51. Valentini M., Napoli A., Tirelli N., and Hubbell J.A. Precise determination of the hydrophobic/hydrophilic junction in polymeric vesicles. Langmuir 19 (2003) 1452-1455